RU2007133108A - АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ - Google Patents
АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ Download PDFInfo
- Publication number
- RU2007133108A RU2007133108A RU2007133108/13A RU2007133108A RU2007133108A RU 2007133108 A RU2007133108 A RU 2007133108A RU 2007133108/13 A RU2007133108/13 A RU 2007133108/13A RU 2007133108 A RU2007133108 A RU 2007133108A RU 2007133108 A RU2007133108 A RU 2007133108A
- Authority
- RU
- Russia
- Prior art keywords
- epha2
- immunoglobulin
- binding fragment
- antigen
- pta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Claims (23)
1. По существу, очищенный иммуноглобулин или его антигенсвязывающий компонент, представляющий собой антитело SPL1, LUCA19, SG5 или LUCA40.
2. По существу, очищенный иммуноглобулин или его антигенсвязывающий компонент, который преимущественно связывается с EphA2 и обладает, по меньшей мере, одной из следующих характеристик SPL1, LUCA19, SG5 или LUCA40:
a. способность связываться с EphA2 на раковой клетке;
b. способность связываться с частью EphA2, которая открыта на поверхности живой раковой клетки in vitro или in vivo;
c. способность препятствовать пролиферации опухолевых клеток, не повышая содержания фосфотирозина в EphA2;
d. способность доставлять терапевтический агент или поддающийся выявлению маркер к раковой клетке, экспрессирующей EphA2; и
e. способность доставлять терапевтический агент или поддающийся выявлению маркер внутрь раковой клетки, экспрессирующей EphA2.
3. Выделенная последовательность нуклеиновой кислоты, кодирующая иммуноглобулин или его антигенсвязывающий фрагмент по п.1.
4. Нуклеиновая кислота по п.3, которая функционально связана промотором.
5. Нуклеиновая кислота по п.4, где промотор и нуклеиновая кислота заключены в экспрессирующем векторе.
6. Нуклеиновая кислота по п.3, кодирующая иммуноглобулин, который представляет собой моноклональное антитело.
7. Клеточная линия, трансфицированная, трансформированная или инфицированная вектором, который содержит нуклеиновую кислоту по п.3.
8. Способ получения, по существу, очищенного иммуноглобулина или его антигенсвязывающего фрагмента, включающий стадии:
a. выращивания клеточной линии, трансформированной нуклеиновой кислотой по п.3, в таких условиях, когда экспрессируется иммуноглобулин или антигенсвязывающий фрагмент; и
b. сбора экспрессированного иммуноглобулина или фрагмента.
9. Способ по п.8, где клеточная линия представляет собой гибридому.
10. Способ по п.9, где гибридома представляет собой гибридому ATCC № PTA-5070, PTA-6056 или PTA-6059 либо гибридому SG3.15B4.1F9.
11. Способ по п.8, где иммуноглобулин представляет собой моноклональное антитело.
12. Фармацевтическая композиция, содержащая эффективную дозу очищенного иммуноглобулина или антигенсвязывающего фрагмента по п.1 вместе с фармацевтически приемлемым носителем.
13. Гибридома, депонированная в американской коллекции типовых культур и имеющая инвентарный номер PTA-5070, PTA-6056 или PTA-6059 либо гибридома SG3.15B4.1F9 (PTA-XXXX).
14. Антитело, которое продуцировано гибридомой, депонированной в американской коллекции типовых культур и имеющей инвентарный номер PTA-5070, PTA-6056 или PTA-6059 либо гибридомой SG3.15B4.1F9 (PTA-XXXX).
15. Иммуноглобулин или его антигенсвязывающий фрагмент по п.1, который гуманизирован.
16. Иммуноглобулин или его антигенсвязывающий фрагмент по п.1, который химеризирован.
17. Иммуноглобулин или его антигенсвязывающий фрагмент по п.1, который представляет собой антитело человека.
18. Иммуноглобулин или его антигенсвязывающий фрагмент по п.1, который представляет собой дериват.
19. Фармацевтическая композиция по п.12, в которой указанный очищенный иммуноглобулин или антигенсвязывающий фрагмент представляет собой LUCA19, LUCA40, SG5 или SPL1.
20. Фармацевтическая композиция по п.12, в которой указанный очищенный иммуноглобулин или антигенсвязывающий фрагмент конкурирует с антителами LUCA19, LUCA40, SG5 или SPL1 за связывание с антигеном EphA2.
21. Фармацевтическая композиция по п.12, в которой очищенный иммуноглобулин или антигенсвязывающий фрагмент гуманизирован.
22. Фармацевтическая композиция по п.12, в которой очищенный иммуноглобулин или антигенсвязывающий фрагмент химеризирован.
23. Способ лечения рака у нуждающегося в этом больного, где указанный способ включает введение указанному больному терапевтически эффективного количества антитела против-EphA2, которое специфически связывается с антигеном EphA2 и обладает, по меньшей мере, одной из следующих характеристик SPL1, LUCA19, SG5 или LUCA40:
a. способность связываться с EphA2 на раковой клетке;
b. способность связываться с частью EphA2, которая открыта на поверхности живой раковой клетки in vitro или in vivo;
c. способность препятствовать пролиферации опухолевых клеток, не повышая содержания фосфотирозина в EphA2;
d. способность доставлять терапевтический агент или поддающийся выявлению маркер к раковой клетке, экспрессирующей EphA2; и
e. способность доставлять терапевтический агент или поддающийся выявлению маркер внутрь раковой клетки, экспрессирующей EphA2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65004705P | 2005-02-04 | 2005-02-04 | |
US60/650,047 | 2005-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2007133108A true RU2007133108A (ru) | 2009-03-10 |
Family
ID=36778009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007133108/13A RU2007133108A (ru) | 2005-02-04 | 2006-02-06 | АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ |
Country Status (17)
Country | Link |
---|---|
US (3) | US7569672B2 (ru) |
EP (1) | EP1846450B1 (ru) |
JP (1) | JP5342145B2 (ru) |
KR (1) | KR101363252B1 (ru) |
CN (2) | CN104059150B (ru) |
AT (1) | ATE551367T1 (ru) |
AU (1) | AU2006210460B2 (ru) |
BR (1) | BRPI0607450A2 (ru) |
CA (1) | CA2597198C (ru) |
CR (1) | CR9332A (ru) |
HK (1) | HK1108163A1 (ru) |
IL (1) | IL184803A (ru) |
MX (1) | MX2007009403A (ru) |
NO (1) | NO20074474L (ru) |
RU (1) | RU2007133108A (ru) |
WO (1) | WO2006084226A2 (ru) |
ZA (1) | ZA200707275B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2598711C2 (ru) * | 2010-07-22 | 2016-09-27 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Антитело к противоопухолевому антигену и способы применения |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7192698B1 (en) * | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
US6927203B1 (en) * | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
US7569672B2 (en) * | 2005-02-04 | 2009-08-04 | Raven Biotechnologies, Inc. | Antibodies that bind to EphA2 and methods of use thereof |
AU2006287416A1 (en) * | 2005-09-07 | 2007-03-15 | Medimmune, Llc | Toxin conjugated Eph receptor antibodies |
ZA200900545B (en) * | 2006-07-18 | 2010-03-31 | Sanofi Aventis | Antagonist antibody against EPHA2 for the treatment of cancer |
EP2109668A4 (en) | 2007-01-22 | 2011-10-05 | Macrogenics West Inc | HUMAN CANCER STEM CELLS |
JP2010530437A (ja) * | 2007-06-18 | 2010-09-09 | メディミューン,エルエルシー | EphA2およびErbB2を発現する細胞の相乗的治療 |
DK2199390T3 (en) | 2007-08-30 | 2017-04-03 | Daiichi Sankyo Co Ltd | ANTI-EphA2 ANTIBODY |
US20110281279A1 (en) * | 2007-12-21 | 2011-11-17 | Siemens Healthcare Diagnostics Inc. | CIRCULATING Epha2 RECEPTOR |
CN102046655B (zh) | 2008-04-02 | 2016-09-14 | 宏观基因有限公司 | Bcr-复合体-特异性抗体和其使用方法 |
JP5117917B2 (ja) | 2008-04-21 | 2013-01-16 | デクセリアルズ株式会社 | 保護素子及びその製造方法 |
JP2012504650A (ja) * | 2008-10-02 | 2012-02-23 | セルタクシス,インコーポレイテッド | 免疫細胞の負の走化性の調節方法 |
SG172254A1 (en) | 2008-12-19 | 2011-07-28 | Macrogenics Inc | Covalent diabodies and uses thereof |
TW201116297A (en) | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
WO2011057251A2 (en) * | 2009-11-09 | 2011-05-12 | The Brigham And Women's Hospital, Inc. | Treatment of heart disease |
DK2498796T3 (en) | 2009-11-09 | 2018-03-05 | Aal Scient Inc | HEART DISEASE TREATMENT |
US8802091B2 (en) | 2010-03-04 | 2014-08-12 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
PL2542256T3 (pl) | 2010-03-04 | 2020-01-31 | Macrogenics, Inc. | Przeciwciała reaktywne wobec b7-h3, ich immunologicznie czynne fragmenty i ich zastosowania |
EP2601216B1 (en) | 2010-08-02 | 2018-01-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
KR102030531B1 (ko) | 2011-05-21 | 2019-10-10 | 마크로제닉스, 인크. | 탈면역화된 혈청-결합 도메인 및 혈청 반감기를 연장하기 위한 그것의 용도 |
MX2014002289A (es) | 2011-08-26 | 2015-03-20 | Merrimack Pharmaceuticals Inc | Anticuerpos fc especificos en tandem. |
WO2013052710A1 (en) * | 2011-10-04 | 2013-04-11 | Expression Pathology, Inc. | Srm/mrm assay for the ephrin type-a receptor 2 protein |
JP5875054B2 (ja) * | 2013-02-13 | 2016-03-02 | 国立大学法人 東京大学 | がんの検査方法及び検査用キット |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
EP2964676A1 (en) | 2013-03-06 | 2016-01-13 | Merrimack Pharmaceuticals, Inc. | Anti-c-met tandem fc bispecific antibodies |
CN106573050B (zh) * | 2014-05-29 | 2021-09-24 | 宏观基因有限公司 | 特异性结合多种癌症抗原的三特异性结合分子和其使用方法 |
KR101636882B1 (ko) * | 2015-06-25 | 2016-07-06 | 전남대학교 산학협력단 | 인간 피브로넥틴 도메인 Ⅲ 기본 골격의 신규 인간 EphA2 특이적 결합 단백질 및 그의 용도 |
EA201890296A1 (ru) | 2015-07-30 | 2018-08-31 | Макродженикс, Инк. | Pd-1-связывающие молекулы и способы их применения |
GEP20217328B (en) | 2015-12-14 | 2021-12-10 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
US11534466B2 (en) | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
BR112018071105A2 (pt) | 2016-04-15 | 2019-02-26 | Macrogenics, Inc. | conjugado de droga e anticorpo, molécula de ligação, composição farmacêutica e uso |
CN110198956A (zh) * | 2017-01-23 | 2019-09-03 | 学校法人东洋大学 | 抗epha2抗体和使用该抗epha2抗体的epha2免疫检测 |
WO2018156740A1 (en) | 2017-02-24 | 2018-08-30 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
KR20200098590A (ko) | 2017-12-12 | 2020-08-20 | 마크로제닉스, 인크. | 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도 |
KR20200121834A (ko) | 2018-02-15 | 2020-10-26 | 마크로제닉스, 인크. | 변이체 cd3-결합 도메인 및 질환 치료를 위한 병용 요법에서의 그것의 용도 |
JP7326764B2 (ja) * | 2018-03-09 | 2023-08-16 | 東ソー株式会社 | 腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法 |
WO2022250431A1 (ko) | 2021-05-25 | 2022-12-01 | 주식회사 박셀바이오 | 모노바디 기반 키메라 항원 수용체 및 이를 포함하는 면역 세포 |
KR20230140746A (ko) * | 2022-03-30 | 2023-10-10 | 연세대학교 산학협력단 | 암전이의 검출용 신규 바이오마커 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6054561A (en) * | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5552391A (en) * | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
GB9115364D0 (en) * | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
CA2078539C (en) * | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5824303A (en) * | 1992-11-13 | 1998-10-20 | Amgen Inc. | Eck receptor ligands |
US6210671B1 (en) * | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US5532159A (en) * | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
US6265150B1 (en) * | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
CA2352471A1 (en) | 1998-12-22 | 2000-06-29 | Raven Biotechnologies, Inc. | Compositions and methods for generating monoclonal antibodies representative of a specific cell type |
EP2312316A1 (en) * | 1999-08-17 | 2011-04-20 | Purdue Research Foundation | Anti-EPHA2 antibodies as a cancer diagnostic |
US6927203B1 (en) * | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
ATE324877T1 (de) | 1999-08-17 | 2006-06-15 | Purdue Research Foundation | Behandlung von metastatischer krankheit |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
US6541225B1 (en) * | 2000-01-26 | 2003-04-01 | Raven Biotechnologies, Inc. | Methods and compositions for generating human monoclonal antibodies |
US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
FR2838742B1 (fr) * | 2002-04-23 | 2004-07-09 | Inst Nat Sante Rech Med | Epitopes t de l'antigene epha2 |
ES2373715T3 (es) * | 2002-05-10 | 2012-02-08 | Medimmune, Llc | Anticuerpos monoclonales frente a epha2 y procedimientos de uso de los mismos. |
CA2485548A1 (en) * | 2002-05-10 | 2004-02-19 | Purdue Research Foundation | Epha2 agonistic monoclonal antibodies and methods of use thereof |
US7569672B2 (en) | 2005-02-04 | 2009-08-04 | Raven Biotechnologies, Inc. | Antibodies that bind to EphA2 and methods of use thereof |
-
2006
- 2006-02-06 US US11/349,327 patent/US7569672B2/en not_active Expired - Fee Related
- 2006-02-06 WO PCT/US2006/004057 patent/WO2006084226A2/en active Application Filing
- 2006-02-06 CN CN201410213409.1A patent/CN104059150B/zh not_active Expired - Fee Related
- 2006-02-06 AU AU2006210460A patent/AU2006210460B2/en not_active Ceased
- 2006-02-06 EP EP06734397A patent/EP1846450B1/en not_active Not-in-force
- 2006-02-06 RU RU2007133108/13A patent/RU2007133108A/ru not_active Application Discontinuation
- 2006-02-06 KR KR1020077019628A patent/KR101363252B1/ko active IP Right Grant
- 2006-02-06 CA CA2597198A patent/CA2597198C/en not_active Expired - Fee Related
- 2006-02-06 CN CN200680011089.5A patent/CN101155830B/zh not_active Expired - Fee Related
- 2006-02-06 AT AT06734397T patent/ATE551367T1/de active
- 2006-02-06 MX MX2007009403A patent/MX2007009403A/es active IP Right Grant
- 2006-02-06 ZA ZA200707275A patent/ZA200707275B/xx unknown
- 2006-02-06 BR BRPI0607450-2A patent/BRPI0607450A2/pt not_active Application Discontinuation
- 2006-02-06 JP JP2007554287A patent/JP5342145B2/ja not_active Expired - Fee Related
-
2007
- 2007-07-24 IL IL184803A patent/IL184803A/en not_active IP Right Cessation
- 2007-08-22 CR CR9332A patent/CR9332A/es not_active Application Discontinuation
- 2007-09-03 NO NO20074474A patent/NO20074474L/no not_active Application Discontinuation
-
2008
- 2008-02-21 HK HK08101935.8A patent/HK1108163A1/xx not_active IP Right Cessation
-
2009
- 2009-06-30 US US12/495,218 patent/US7776328B2/en not_active Expired - Fee Related
- 2009-11-30 US US12/627,335 patent/US8183357B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2598711C2 (ru) * | 2010-07-22 | 2016-09-27 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Антитело к противоопухолевому антигену и способы применения |
Also Published As
Publication number | Publication date |
---|---|
AU2006210460A2 (en) | 2006-08-10 |
US7569672B2 (en) | 2009-08-04 |
HK1108163A1 (en) | 2008-05-02 |
WO2006084226A2 (en) | 2006-08-10 |
AU2006210460A1 (en) | 2006-08-10 |
CA2597198A1 (en) | 2006-08-10 |
ZA200707275B (en) | 2009-01-28 |
CA2597198C (en) | 2016-06-21 |
KR20070107721A (ko) | 2007-11-07 |
CN104059150A (zh) | 2014-09-24 |
JP5342145B2 (ja) | 2013-11-13 |
CR9332A (es) | 2008-03-18 |
ATE551367T1 (de) | 2012-04-15 |
EP1846450A2 (en) | 2007-10-24 |
BRPI0607450A2 (pt) | 2009-09-01 |
NO20074474L (no) | 2007-11-05 |
US8183357B2 (en) | 2012-05-22 |
EP1846450A4 (en) | 2008-05-28 |
US20060177453A1 (en) | 2006-08-10 |
WO2006084226A3 (en) | 2006-11-30 |
US20090263391A1 (en) | 2009-10-22 |
JP2008529497A (ja) | 2008-08-07 |
US20100086969A1 (en) | 2010-04-08 |
EP1846450B1 (en) | 2012-03-28 |
CN101155830A (zh) | 2008-04-02 |
KR101363252B1 (ko) | 2014-02-13 |
AU2006210460B2 (en) | 2012-04-05 |
CN104059150B (zh) | 2018-10-02 |
IL184803A (en) | 2011-04-28 |
MX2007009403A (es) | 2007-10-02 |
CN101155830B (zh) | 2014-06-18 |
US7776328B2 (en) | 2010-08-17 |
IL184803A0 (en) | 2007-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007133108A (ru) | АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ | |
AU2018223053B2 (en) | Novel modulators and methods of use | |
JP2008529497A5 (ru) | ||
ES2829206T3 (es) | Moduladores novedosos y procedimientos de uso | |
JP6515111B2 (ja) | 新規の抗クローディン抗体および使用方法 | |
JP3213314B2 (ja) | 幹細胞因子レセプターに対するモノクローナル抗体 | |
JP5631733B2 (ja) | 抗EpCAM抗体およびその使用 | |
US20190022241A1 (en) | Novel sez6 modulators and methods of use | |
JP2002515511A (ja) | 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療 | |
US9056911B2 (en) | Antibody against carcinoembryonic antigen and uses thereof | |
JP2016509014A (ja) | 新規の多特異的構成物 | |
JP2018138034A (ja) | 抗her2抗体及びその結合体 | |
RU2012137515A (ru) | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения | |
RU2014113304A (ru) | Анти-cd40-антитела, применение и методы | |
JP2017500028A (ja) | 新規の抗dpep3抗体および使用方法 | |
JP2005514409A (ja) | Muc18抗原に対する抗体の使用 | |
NZ597067A (en) | Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer | |
JP2014515600A5 (ru) | ||
KR102486507B1 (ko) | 플렉틴-1 결합 항체 및 그의 용도 | |
JP2020522280A5 (ru) | ||
JP2020522281A5 (ru) | ||
CN110642950B (zh) | 一种人源化t细胞活化的v域免疫抑制因子抗原结合片段 | |
JP2024514855A (ja) | Dll3に対する結合分子及びその使用 | |
WO2024077775A1 (zh) | 一种多功能重组抗体及其制备方法和应用 | |
JP6831836B2 (ja) | 癌治療のための抗−サバイビン抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20090313 |